Previous 10 | Next 10 |
CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR...
2023-04-21 16:46:43 ET Summary The market is discounting the lucrative $600M partnership with GSK. Multiple pipeline catalysts will occur in 2023 with Phase 3 readout anticipated in early 2024. Market cap is only $90M and they have 109M in cash & cash equivalents. Shar...
CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (M...
2023-03-30 22:11:06 ET Spero Therapeutics, Inc. (SPRO) Q4 2022 Earnings Conference Call March 30, 2023, 16:30 ET Company Participants Ted Jenkins - VP & Head, IR Ankit Mahadevia - Co-Founder, President, CEO & Director Kamal Hamed - Chief Medical Officer ...
2023-03-30 16:30:12 ET Spero Therapeutics press release ( NASDAQ: SPRO ): Q4 GAAP EPS of $0.55 beats by $0.51 . Revenue of $47.44M (+1631.4% Y/Y) beats by $24.57M . Shares +9.7% . For further details see: Spero Therapeutics GAAP EPS of $0.55 beats...
Initiated proof-of-concept Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); top line data expected in 1H 2024 Exclusive license agreement with GSK for tebipenem HBr provided Spero with $66 million upfront, a $9 million direct equity investment, and eli...
2023-03-29 17:35:59 ET Major earnings expected after the bell on Thursday include: BlackeBerry Limited ( BB ) Skillz ( SKLZ ) Canoo ( GOEV ) IonQ ( IONQ ) Astra Space ( ASTR ) For further details see: Notable earnings after Thursday's close
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas, involving rare diseases and multi-drug resistant (...
2023-03-12 18:35:00 ET Spero Therapeutics ( NASDAQ: SPRO ) is scheduled to announce Q4 earnings results on Monday, March 13, after market close. The consensus EPS Estimate is -$0.34 (+62.2% Y/Y) and the consensus Revenue Estimate is $22.87M (+734.7% Y/Y). Over the last...
2023-03-12 17:35:16 ET Major earnings expected after the bell on Monday include: WestPort Fuel Systems ( WPRT ) T2 Biosystems ( TTOO ) Omeros corporation ( OMER ) Turtle beach corporation ( HEAR ) Avid Bioservices ( CDMO ) For further details ...
News, Short Squeeze, Breakout and More Instantly...
Spero Therapeutics Inc. Company Name:
SPRO Stock Symbol:
NASDAQ Market:
Spero Therapeutics Inc. Website:
CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced t...
CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced tha...
On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024 Enrollment ongoing in PIVOT-PO, a pivotal Phase 3 clinical trial of oral tebipenem HBr in cUTI Received FDA Fast...